Clinical Research Directory
Browse clinical research sites, groups, and studies.
VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization
Sponsor: Science Valley Research Institute
Summary
Venous thromboembolism (VTE) has a high prevalence in patients with multiple comorbidities undergoing complex surgical procedures. Sometimes, extended prophylaxis for VTE with KLMWH or direct oral anticoagulants (DOACs) is necessary. Currently, there is no consensus in the literature regarding the use of DOACs for extended VTE prophylaxis in patients undergoing lower limb revascularization (LLR). Objective: To evaluate the use of DOACs (already approved to reduce MACE and MALE) in VTE prophylaxis in patients undergoing LLR.
Official title: Incidence of Venous Thromboembolism After Lower Limb Revascularization in Patients Receiving Rivaroxaban 2.5 Mg Bid + Aspirin 100 Mg Versus Single Antiplatelet Treatment - a Randomized Clinical Trial
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2024-02-24
Completion Date
2025-07-30
Last Updated
2025-03-12
Healthy Volunteers
No
Conditions
Interventions
rivaroxaban 2.5 mg bid + aspirin 100 mg
rivaroxaban 2.5 mg bid + aspirin
clopidogrel 75 mg od for 3 months followed by aspirin 100 mg od for endovascular procedures or aspirin for open procedures
comparator
Locations (1)
Hospital das Clínicas, Federal University of Pernambuco
Pernambuco, Pernambuco, Brazil